SK111697A3 - Using alendronate for lessening the risk of vertebral fractures - Google Patents

Using alendronate for lessening the risk of vertebral fractures Download PDF

Info

Publication number
SK111697A3
SK111697A3 SK1116-97A SK111697A SK111697A3 SK 111697 A3 SK111697 A3 SK 111697A3 SK 111697 A SK111697 A SK 111697A SK 111697 A3 SK111697 A3 SK 111697A3
Authority
SK
Slovakia
Prior art keywords
alendronate
fractures
vertebral
years
risk
Prior art date
Application number
SK1116-97A
Other languages
English (en)
Slovak (sk)
Inventor
David B Karpf
Thomas P Capizzi
Hui Quan
Arthur C Ii Santora
Ashley J Yates
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of SK111697A3 publication Critical patent/SK111697A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1116-97A 1995-02-17 1996-02-13 Using alendronate for lessening the risk of vertebral fractures SK111697A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/389,860 US20010051616A1 (en) 1995-02-17 1995-02-17 Method of lessening the risk of vertebral fractures
PCT/US1996/001946 WO1996025166A1 (en) 1995-02-17 1996-02-13 Method of lessening the risk of vertebral fractures

Publications (1)

Publication Number Publication Date
SK111697A3 true SK111697A3 (en) 1998-02-04

Family

ID=23540050

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1116-97A SK111697A3 (en) 1995-02-17 1996-02-13 Using alendronate for lessening the risk of vertebral fractures

Country Status (14)

Country Link
US (1) US20010051616A1 (ja)
EP (1) EP0809503A4 (ja)
JP (1) JPH11501906A (ja)
KR (1) KR19980702209A (ja)
CN (1) CN1181008A (ja)
AU (1) AU689379B2 (ja)
CA (1) CA2213076A1 (ja)
EA (1) EA000348B1 (ja)
HU (1) HUP9802077A3 (ja)
NZ (1) NZ303476A (ja)
PL (1) PL321836A1 (ja)
SK (1) SK111697A3 (ja)
WO (1) WO1996025166A1 (ja)
ZA (1) ZA961234B (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6416737B1 (en) * 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
CN100479823C (zh) * 2001-12-21 2009-04-22 宝洁公司 双膦酸盐在制造药物套盒中的用途以及用于增加骨质的套盒
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
WO2003057136A2 (en) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
ES2532393T3 (es) * 2002-05-10 2015-03-26 F. Hoffmann-La Roche Ag Acidos bisfosfónicos para tratamiento y prevención de osteoporosis
NZ536273A (en) 2002-12-20 2007-08-31 Hoffmann La Roche High dose ibandronate formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
EP0600834A1 (en) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery

Also Published As

Publication number Publication date
AU4979996A (en) 1996-09-04
HUP9802077A2 (hu) 2000-06-28
EA000348B1 (ru) 1999-04-29
CN1181008A (zh) 1998-05-06
EA199700185A1 (ru) 1997-12-30
US20010051616A1 (en) 2001-12-13
MX9706275A (es) 1997-11-29
PL321836A1 (en) 1997-12-22
NZ303476A (en) 2000-07-28
JPH11501906A (ja) 1999-02-16
KR19980702209A (ko) 1998-07-15
ZA961234B (en) 1996-08-27
HUP9802077A3 (en) 2001-10-29
WO1996025166A1 (en) 1996-08-22
EP0809503A4 (en) 2001-12-05
EP0809503A1 (en) 1997-12-03
CA2213076A1 (en) 1996-08-22
AU689379B2 (en) 1998-03-26

Similar Documents

Publication Publication Date Title
Pleiner-Duxneuner et al. Treatment of osteoporosis with parathyroid hormone and teriparatide
US5804570A (en) Method of lessening the risk of non-vertebral bone fractures
JP6198346B2 (ja) 1回当たり100〜200単位のpthが週1回投与されることを特徴とする、pth含有骨粗鬆症治療/予防剤
EA000964B1 (ru) Способ лечения или предупреждения остеопороза
SK111697A3 (en) Using alendronate for lessening the risk of vertebral fractures
Kitagawa et al. Oral alendronate treatment for polyostotic fibrous dysplasia: a case report
Massarella et al. Effect of renal impairment on the pharmacokinetics of cibenzoline
US20020169148A1 (en) Use of alendronate for the prevention of osteoporosis
McClung et al. Review of risedronate in the treatment of osteoporosis
SK159597A3 (en) Use of alendronate for the prevention of osteoporosis
CZ259097A3 (en) Pharmaceutical preparation for reducing risk of bone fractures
TW201105332A (en) Agent for preventing forearm bone fracture which comprises eldecalcitol
MXPA97006275A (en) The use of alendronate to prepare compositions to reduce the risk of vertebra fractures
CN1187130A (zh) 用二磷酸盐预防与免疫抑制疗法有关的骨损失
MXPA97006277A (en) The use of alendronate to prepare compositions to reduce the risk of non-vertebrate bit fractures
MXPA97009906A (en) Use of bisphosphonates to prepare compositions to prevent loss of associated bone conterapia immunosupres